Zilebesiran RNA干扰治疗轻度至中度高血压:KARDIA-1随机临床试验
这项2期随机双盲剂量探索研究在4国78个中心纳入394例轻度至中度高血压成人,比较不同zilebesiran皮下方案与安慰剂。治疗3个月时,各zilebesiran方案24小时动态收缩压较基线降幅均显著大于安慰剂,不良反应以注射部位反应和轻度高钾血症为主。
要点
- zilebesiran 150 mg每6个月、300 mg每3或6个月、600 mg每6个月,3个月时24小时动态收缩压较基线降幅均显著大于安慰剂。
- 6个月内zilebesiran组不良事件60.9%、安慰剂组50.7%;严重不良事件分别为3.6%和6.7%。
- 非严重药物相关不良事件zilebesiran组16.9%、安慰剂组8.0%,主要为注射部位反应和轻度高钾血症。
核心结论
- 在轻度至中度高血压成人中,zilebesiran多种剂量以3个月或6个月间隔给药,在3个月时显著降低24小时平均动态收缩压。
研究设计与样本
- 2期随机双盲剂量探索研究,在4个国家78个中心开展,zilebesiran与安慰剂比较。
- 筛选于2021年7月开始,6个月研究的末例患者访视于2023年6月完成。
- 受试者为停用降压药后日间平均动态收缩压135至160 mm Hg的轻度至中度高血压成人。
- 随机接受4种皮下zilebesiran方案之一(150、300或600 mg每6个月一次,或300 mg每3个月一次)或安慰剂(每3个月一次)治疗6个月。
- 394例随机患者中377例(zilebesiran 302例、安慰剂75例)构成全分析集;93例黑人(24.7%),167例女性(44.3%),平均(SD)年龄57(11)岁。
主要发现
- 3个月时24小时平均动态收缩压较基线变化:zilebesiran 150 mg每6个月一次为-7.3 mm Hg(95%CI,-10.3至-4.4);300 mg每3或6个月一次为-10.0 mm Hg(95%CI,-12.0至-7.9);600 mg每6个月一次为-8.9 mm Hg(95%CI,-11.9至-6.0);安慰剂为6.8 mm Hg(95%CI,3.6至9.9)。
- 3个月时较基线变化的最小二乘均值组间差异对比安慰剂:zilebesiran 150 mg每6个月一次为-14.1 mm Hg(95%CI,-19.2至-9.0;P < .001);300 mg每3或6个月一次为-16.7 mm Hg(95%CI,-21.2至-12.3;P < .001);600 mg每6个月一次为-15.7 mm Hg(95%CI,-20.8至-10.6;P < .001)。
- 6个月内,zilebesiran组60.9%患者发生不良事件,安慰剂组50.7%;严重不良事件zilebesiran组3.6%,安慰剂组6.7%。
- 非严重药物相关不良事件发生于zilebesiran治疗患者的16.9%(主要为注射部位反应和轻度高钾血症)和安慰剂治疗患者的8.0%。
关键数值与推荐
- 主要终点为3个月时24小时平均动态收缩压较基线变化的最小二乘均值组间差异。
- 轻度至中度高血压定义为停用降压药后日间平均动态收缩压135至160 mm Hg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Angiotensinogen is the most upstream precursor of the renin-angiotensin-aldosterone system, a key pathway in blood pressure (BP) regulation. Zilebesiran, an investigational RNA interference therapeutic, targets hepatic angiotensinogen synthesis. OBJECTIVE: To evaluate antihypertensive efficacy and safety of different zilebesiran dosing regimens. DESIGN, SETTING, AND PARTICIPANTS: This phase 2, randomized, double-blind, dose-ranging study of zilebesiran vs placebo was performed at 78 sites across 4 countries. Screening initiation occurred in July 2021 and the last patient visit of the 6-month study occurred in June 2023. Adults with mild to moderate hypertension, defined as daytime mean ambulatory systolic BP (SBP) of 135 to 160 mm Hg following antihypertensive washout, were randomized. INTERVENTIONS: Randomization to 1 of 4 subcutaneous zilebesiran regimens (150, 300, or 600 mg once every 6 months or 300 mg once every 3 months) or placebo (once every 3 months) for 6 months. MAIN OUTCOMES AND MEASURES: The primary end point was between-group difference in least-squares mean (LSM) change from baseline to month 3 in 24-hour mean ambulatory SBP. RESULTS: Of 394 randomized patients, 377 (302 receiving zilebesiran and 75 receiving placebo) comprised the full analysis set (93 Black patients [24.7%]; 167 [44.3%] women; mean [SD] age, 57 [11] years). At 3 months, 24-hour mean ambulatory SBP changes from baseline were -7.3 mm Hg (95% CI, -10.3 to -4.4) with zilebesiran, 150 mg, once every 6 months; -10.0 mm Hg (95% CI, -12.0 to -7.9) with zilebesiran, 300 mg, once every 3 months or every 6 months; -8.9 mm Hg (95% CI, -11.9 to -6.0) with zilebesiran, 600 mg, once every 6 months; and 6.8 mm Hg (95% CI, 3.6-9.9) with placebo. LSM differences vs placebo in change from baseline to month 3 were -14.1 mm Hg (95% CI, -19.2 to -9.0; P < .001) with zilebesiran, 150 mg, once every 6 months; -16.7 mm Hg (95% CI, -21.2 to -12.3; P < .001) with zilebesiran, 300 mg, once every 3 months or every 6 months; and -15.7 mm Hg (95% CI, -20.8 to -10.6; P < .001) with zilebesiran, 600 mg, once every 6 months. Over 6 months, 60.9% of patients receiving zilebesiran had adverse events vs 50.7% patients receiving placebo and 3.6% had serious adverse events vs 6.7% receiving placebo. Nonserious drug-related adverse events occurred in 16.9% of zilebesiran-treated patients (principally injection site reactions and mild hyperkalemia) and 8.0% of placebo-treated patients. CONCLUSIONS AND RELEVANCE: In adults with mild to moderate hypertension, treatment with zilebesiran across a range of doses at 3-month or 6-month intervals significantly reduced 24-hour mean ambulatory SBP at month 3. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04936035.
引用
- Bakris GL, Saxena M, Gupta A, et al. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024. PMID: 38363577. doi:10.1001/jama.2024.0728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。